Drug-Disease Interaction

Drug-disease interaction describes altered pharmacokinetics or pharmacodynamics from concurrent disease states compromising therapeutic efficacy or increasing toxicity. Renal impairment reduces renally-eliminated drug clearance increasing accumulation. Hepatic dysfunction impairs metabolism altering elimination kinetics. Cardiovascular disease compromises cardiac output reducing drug distribution. Gastrointestinal disease alters drug absorption and metabolism.

Population pharmacokinetic analysis identifies disease-related pharmacokinetic alterations. Regulatory labelling incorporates disease-based dose adjustment recommendations. Therapeutic drug monitoring guides individualised dosing in diseased patients. Biomarkers predicting disease-related alterations optimise dose selection. Post-approval pharmacovigilance detects unexpected disease-related adverse events warranting investigation.